TORONTO, ON, CANADA / NOVEMBER 29, 2022 - Ripple Therapeutics Corporation, a clinical stage ophthalmic therapeutics company, today announced Jonathan Talamo, M.D., currently a member of its Board, has been appointed as the new Chair of its Board of Directors. 

Dr. Talamo is internationally known as an experienced surgeon and thought leader in ophthalmology. Following 25 years in clinical practice, Dr. Talamo served as the Chief Medical Officer at Ocular Therapeutix, an ophthalmic drug delivery company, where he oversaw development programs in multiple therapeutic areas, including post–cataract surgery inflammation, dry eye, allergy, glaucoma and retinal vascular diseases. Most recently, he served as  Chief Medical Officer and Worldwide VP of Clinical and Medical Affairs at Johnson and Johnson Vision. While at J&J, Dr. Talamo helped lead the integration of Abbott Medical Optics as well as the development and launch of numerous innovative products.

“It’s an exciting time at Ripple Therapeutics, with licensing agreements in place and a clinical trial well underway for IBE-814 IVT (treating DME and RVO) and progress towards the clinic with RTC-1119 (treating glaucoma)”, commented Dr. Talamo. “I’m looking forward to working even more closely with the Ripple Board and team to bring important, proprietary extended-release ophthalmic therapeutics to market that address significant unmet needs for patients and clinicians.”

“With his clinical experience as an ophthalmologist and industry experience with both large and small companies, Jon has already brought tremendous insight to our Board”, stated Tom Reeves, President and CEO, Ripple Therapeutics. “Now as Chair, we look forward  to his leadership as we work to realize our vision of developing novel therapeutics that provide better outcomes for patients, easier management of care for physicians and lower costs for payors.”

About Ripple Therapeutics

Ripple Therapeutics Corporation is a clinical stage, privately held company that is focused on ophthalmic therapeutics with controllable, sustainable drug delivery. The core feature of Ripple’s Epidel™ technology is the ability to engineer sustained-release pharmaceuticals with zero-order release kinetics without the use of polymers or excipients. Ripple’s novel therapeutics provide for better outcomes for patients, easier management of care for physicians and lower costs for payors.  Ripple has a full product pipeline in development. www.rippletherapeutics.com

Media Contact:

Julie Fotheringham, V.P. Marketing, People & Culture

M: 416-951-7988 E: jfotheringham@rippletherapeutics.com